Phase 1 Active, Not Recruiting
GSK4771261
Sponsor
GlaxoSmithKline
Trial Name
Phase 1a/1b Single Ascending Dose
Start Date
2024-12
Est. Completion
2027-07
Participants
86
Location
London, UK
NCT ID
NCT06734234Mechanism
Undisclosed target. Immunogenicity (anti-drug antibody) endpoints indicate a biologic rather than a small molecule; GSK has not published the mechanism.
Detailed article coming soon. See the trial details above for current information.
Disclaimer: This information is for educational purposes only and is not medical advice. Clinical trial information is based on publicly available data from ClinicalTrials.gov and published research. Consult your nephrologist before making treatment decisions.